file,ref_number,ref_text,doi,doi_url,titleDoi,firstAuthDoi,author_similarity,title_similarity
experiments/glioblastoma_survival/ai_messages/high_complexity--generated_NF1_MGMT_medium_methylated,[1],"Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. 2017. Neurology. Neurofibromatosis type 1.",10.1038/nrdp.2017.4,https://doi.org/10.1038/nrdp.2017.4,Neurofibromatosis type 1,Gutmann,100,100
experiments/glioblastoma_survival/ai_messages/high_complexity--generated_NF1_MGMT_medium_methylated,[2],"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. 2005. N Engl J Med. MGMT gene silencing and benefit from temozolomide in glioblastoma.",10.1056/nejmoa043331,https://doi.org/10.1056/nejmoa043331,<i>MGMT</i>Gene Silencing and Benefit from Temozolomide in Glioblastoma,Hegi,100,98
experiments/glioblastoma_survival/ai_messages/high_complexity--generated_NF1_MGMT_medium_methylated,[3],"Omuro A, DeAngelis LM. 2013. JAMA. Glioblastoma and other malignant gliomas: a clinical review.",10.1001/jama.2013.280319,https://doi.org/10.1001/jama.2013.280319,Glioblastoma and Other Malignant Gliomas,Omuro,100,100
experiments/glioblastoma_survival/ai_messages/high_complexity--generated_NF1_MGMT_medium_methylated,[4],"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. 2005. N Engl J Med. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.",10.1056/nejmoa043330,https://doi.org/10.1056/nejmoa043330,Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma,Stupp,100,100
